PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026

LONDON, Jan. 15, 2018 /PRNewswire/ -- Summary



Download the full report: https://www.reportbuyer.com/product/5284470


Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. Seizures result from abnormal electrical discharges in the brain and vary in their manifestations, from the brief staring spells that are characteristic of absence seizures to full-body convulsions known as tonic-clonic seizures.

Epilepsy can be considered a spectrum disorder due to its different causes, different seizure types, and different disease severities. Many different epilepsy syndromes have been characterized, with some of these syndromes appearing to be hereditary, while others have unknown causes.

It is estimated that sales of anti-epileptic drugs (AEDs) in the epilepsy market were approximately $6.1B throughout the 7MM in 2016. The highest selling drug in the epilepsy market was UCB's Vimpat (lacosamide). With that global sales in the epilepsy market are expected to grow at a moderate Compound Annual Growth Rate (CAGR) of 2.1%. The main driver of growth will be the launch of five late-stage pipeline drugs, in particularly GW Pharmaceutical's Epidiolex (cannabidiol) and Zogenix'sfenfluramine, which target rare, orphan epilepsy syndromes.

The major drivers of growth in the epilepsy market during the forecast period include -
- The launch and uptake of GW Pharmaceutical's Epidiolex and Zogenix'sfenfluramine, which are expected to be approved in Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
- The launch and uptake of Upsher-Smith Laboratories' USL-261 and Neurelis' NRL-1, which will be approved for the treatment of acute repetitive seizures. These reformulations are expected to drastically increase compliance.
- The high annual cost of therapy for pipeline drugs means they will generate high sales and drive growth.

Future key players in the epilepsy market are acquiring companies or entering into partnerships for the co-development and co-marketing of products into different regions of the 7MM. This strategy provides an effective method for companies to join efforts and resources, to share the costs and risks of R&D, and to maximize the commercial potential of the marketed products.

Lundbeck is the company that has embraced this strategy more than others. It entered into a partnership with Sanofi to market Sabril and Onfi in the US, while Sanofi takes marketing responsibilities in the EU.

The report "PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026", provides overview of epilepsy, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following -
- Annualized epilepsy therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (focal, generalized, and unclassified seizures) forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the epilepsy therapeutics market
- Pipeline analysis: Comprehensive data assessing emerging trends and mechanisms of action under development for epilepsy therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global epilepsy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report:GW Pharmaceuticals, Zogenix, UCB, Upsher-Smith Laboratories, Neurelis, Lundbeck, Sanofi, Pfizer, SK Biopharmaceuticals, Supernus Pharmaceuticals, Daiichi-Sankyo

Scope
- Overview of epilepsy, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized epilepsy therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (focal, generalized, and unclassified seizures) forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the epilepsy therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for epilepsy therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global epilepsy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global epilepsy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global epilepsy therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Download the full report: https://www.reportbuyer.com/product/5284470

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +1 (646) 453 6293
Website: www.reportbuyer.com  

SOURCE ReportBuyer

Related Links

http://www.reportbuyer.com